Robertson, John F. R.
Jiang, Zefei
Di Leo, Angelo
Ohno, Shinji
Pritchard, Kathleen I.
Ellis, Matthew
Bradbury, Ian
Campbell, Christine
Funding for this research was provided by:
AstraZeneca
Article History
Received: 31 October 2018
Accepted: 22 April 2019
First Online: 11 May 2019
Compliance with ethical standards
:
: This work was supported by AstraZeneca. JFRR has received consulting fees from, and performed contracted research on behalf of, AstraZeneca, Bayer, Novartis, and Oncimmune; has given expert testimony for AstraZeneca; and holds stock with Oncimmune. ADL has received consulting fees from AstraZeneca, Novartis, Pfizer, and Roche; and has performed contracted research on behalf of AstraZeneca and Pfizer. SO has received honoraria from AstraZeneca, Chugai, Eisai, Kyowa Hakko Kirin, Novartis, Pfizer, Sanofi, and Taiho; and has performed contracted research on behalf of AstraZeneca, Daiichi Sankyo, and Taiho. KIP has received consulting fees from Amgen, AstraZeneca, Eisai, GlaxoSmithKline, Novartis, Pfizer, and Roche; and has performed contracted research on behalf of AstraZeneca, Eisai, Novartis, and Roche. ME has received consulting fees from AbbVie, AstraZeneca, Lilly, Merck, Nanostring, Novartis, Pfizer, and Zeno. ZJ, IB, and CC have declared that they have no conflicts of interest.